Freshly Listed Biotech Firm Delivers 60% Gains

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.

While headlines focus on the same overhyped AI names, a bigger opportunity is taking shape — and it’s flying under the radar.

A new report reveals 9 AI companies with real U.S. operations, accelerating revenue, and deep AI integration. These aren’t speculative plays — they’re positioned to benefit from a massive shift in how and where AI is being built.

This free guide includes:

…plus 6 more names with major upside potential.

The early window on these opportunities may be closing — now’s the time to see what’s coming next.

[Get your FREE copy now]

Wall Street fell Monday as President Trump’s surprise 25% tariffs on South Korean and Japanese goods reignited fears of a global trade war and economic retaliation.

CoreWeave (NASDAQ: CRWV) has announced plans to acquire Core Scientific in an all-stock deal valued at $9 billion, which will significantly expand its data center footprint and reduce long-term infrastructure costs.

The transaction, expected to close in Q4 2025 pending regulatory and shareholder approval, positions CoreWeave to absorb 1.3 gigawatts of gross power capacity, with an additional gigawatt available for future growth.

Core Scientific, which emerged from bankruptcy in 2024 and pivoted toward compute infrastructure, brings both scale and access to power, two key assets in the capital-intensive AI hardware race.

For existing CoreWeave shareholders, the acquisition deepens vertical integration.

The company will no longer rely as heavily on third-party colocation leases, giving it direct control over real estate, power, and operational timelines.

That shift could improve margins and increase agility as AI demand accelerates and hyperscalers look for predictable compute access.

Those considering a position in CoreWeave should assess the strategic logic behind absorbing a former miner-turned-AI infra provider.

While the dilution is notable, owning infrastructure outright may give CoreWeave more pricing power in future AI compute contracts.

The company is signaling a long-term shift toward embedded, self-owned capacity overgrowth through leasing.

Following the close, Core Scientific shareholders will receive 0.1235 CoreWeave shares for each share they hold, translating to approximately $20.40 per share, a 66% premium to the pre-deal stock price.

But with less than 10 percent ownership in the combined company, the upside will depend on CoreWeave’s ability to execute and scale from here.

Every strong portfolio starts with a reliable core — and this new report may help investors build exactly that.

“7 Stocks to Buy and Hold Forever” highlights a group of companies with a track record of steady performance, strong fundamentals, and long-term growth potential.

For a limited time, this full report is being offered at no cost.

These stocks were chosen for a reason — and could help lay the groundwork for a strategy built to outlast short-term swings.

[Access the report free here]

Johnson & Johnson (NYSE: JNJ) is doubling down on its U.S. innovation pipeline as mounting pressure from China weighs on its performance in medical technology (MedTech).

Despite macro challenges in Asia Pacific, the company’s second-half outlook is being shaped by domestic product launches and acquisitions that are beginning to reshape its core device business.

Sales in China continue to face headwinds from ongoing procurement mandates and regulatory clampdowns. The company does not expect relief in that market this year.

But in contrast, new momentum is building in the U.S. thanks to strong uptake from Abiomed and Shockwave acquisitions, as well as progress on the OTTAVA robotic surgery system and VARIPULSE ablation technology.

For long-term J&J holders, this pivot represents a deliberate shift away from volume-based exposure toward differentiated, technology-led categories.

Rather than rely on any single geography, the company is redirecting resources into markets with more pricing stability and clinical leadership potential.

Those eyeing a future position in J&J may find the direction clearer now.

A pipeline anchored in U.S. regulatory approvals, targeted innovation, and capital discipline puts the MedTech unit on steadier footing.

Geographic diversification and portfolio depth are starting to outweigh the downside from China’s procurement drag.

With fewer one-time sales disruptions in the U.S. and more regulatory clarity on the horizon, J&J anticipates stronger MedTech performance in the second half of 2025.

As we dive into Q2 2025, the stock market is buzzing with opportunities, and I’ve got the insider scoop just for you.

I’ve handpicked the Top Seven Stocks for this quarter, offering you a clear roadmap for growth as the year progresses.

Here’s what makes this guide indispensable:

This isn’t merely a list; it’s your chance to seize the market’s hottest opportunities before they pass you by.

[Get Your Free Guide Now]

These names aren’t flashy, but they combine three things that matter most to long-term investors: strong payouts, low valuations, and business models that can weather volatility.

At a time when valuations are stretched and growth feels priced in, these stocks are 

starting to look like a smart place to park capital.

Bank of America

BAC (NYSE: BAC) has quietly become one of the top-performing financials of 2025, up more than 11 percent this year.

The stock trades at a forward P/E of just 11.5, while paying a 2 percent dividend.

The payout ratio remains conservative at 30 percent, and the company has increased its dividend for 11 straight years.

Technically, BAC just cleared major resistance around $48. That breakout signals potential for further gains, especially with earnings on deck.

Analysts remain bullish, with a consensus Moderate Buy rating across 26 firms.

With financials leading the market, BAC stands out as a rare combo of income, momentum, and value.

Altria Group

Altria (NYSE: MO) doesn’t get much love in fast-money circles, but it’s one of the most reliable options in the market.

The current yield stands at 6.8 percent, supported by a payout history spanning over 50 years. The stock trades at just 10 times earnings and has gained 14 percent this year.

Investors often question whether the tobacco model has staying power.

Altria has already begun shifting its focus to smokeless nicotine products and owns a significant stake in JUUL.

It’s not growth that makes MO attractive, but it’s dependable cash flow and defensive strength during market drawdowns.

Ford Motor Company

Ford (NYSE: F) still trades like it’s stuck in the past. But beneath the surface, it’s a high-yield turnaround bet that’s already showing signs of progress.

The stock yields over 5 percent and trades at just 8.9 times forward earnings.

Management has focused on improving profitability in the second half of the year, particularly as EV cost pressures ease.

While Wall Street remains cautious, investors focused on cash flow and value will find the risk-reward setup hard to ignore.

For those willing to wait, Ford offers real upside paired with meaningful income.

Why Value Still Has the Last Word

For investors tired of chasing hype cycles, these names offer something different: consistency, cash flow, and valuation support.

They may not lead every rally, but they rarely break portfolios either.

As market leadership continues to rotate and rate cuts linger in the background, the appeal of steady income and low multiples only grows stronger.

Sometimes the smartest plays are the ones that don’t need a spotlight to perform.

👉 Click here to get our closing report to your cell for free!

Pelthos Therapeutics Inc [PTHS] $25.96 (+60.40%)

Pelthos soared after completing its merger deal, securing an $18 million investment from Ligand, and plans to launch ZELSUVMI, the first at-home treatment for molluscum.

Artelo Biosciences Inc [ARTL] $14.32 (+42.49%)

Artelo jumped after presenting new preclinical data showing its lead candidate, ART12.11, produced antidepressant effects equal to or better than Zoloft in animal models.

Cogent Biosciences Inc [COGT] $9.36 (+23.55%)

Cogent climbed after its bezuclastinib trial met all endpoints with highly significant results in treating non-advanced systemic mastocytosis.

Apogee Therapeutics Inc [APGE] $39.24 (-17.32%)

Apogee stock sank as investors questioned whether its eczema drug meaningfully outperforms existing market leaders, despite positive trial results.

Core Scientific Inc [CORZ] $14.83 (-17.61%)

Core Scientific shares dropped after agreeing to be acquired by CoreWeave for $9 billion in an all-stock deal, which values the company at a discount to recent trading levels. 

AIFU Inc [AIFU] $5.96 (-14.12%)

AIFU shares plunged after announcing a private placement priced far below market value, raising dilution concerns among existing shareholders.

Starting this July, big banks can legally treat gold as cash—and they’re wasting no time.

Meanwhile, millions of Americans are still heavily invested in volatile paper assets.

One economist says gold is now “the only money banks trust.”

There’s still time to catch up, using an IRS-approved method that avoids taxes or penalties.

This FREE Wealth Protection Guide explains how to move before the window closes.

[Click here to access the guide]

P.S. Every day you wait, the insiders move further ahead. Get the facts before July hits.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.